ITeos Therapeutics Down Over 29%, on Pace for Largest Percent Decrease Since May 2022 -- Data Talk
ITeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Market-Moving News for September 16th
ITeos Therapeutics Price Target Maintained With a $46.00/Share by HC Wainwright & Co.
ITeos Therapeutics Analyst Ratings
Piper Sandler Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $36
Piper Sandler analyst Christopher Raymond maintains $ITeos Therapeutics(ITOS.US)$ with a buy rating, and maintains the target price at $36.According to TipRanks data, the analyst has a success rate